August, 8, 2007 - The Medicines Company announced that the new guidelines released yesterday by the American College of cardiology (ACC) and the American Heart Association (AHA) grant a Class I (level of evidence B) recommendation that Angiomax "should be administered" as one of the choices for anticoagulant therapy for patients with unstable angina (UA) and non-ST-elevated myocardial infarction (NSTEMI) who are selected to receive an invasive strategy.
